



PsiOxus

THERAPEUTICS

Smart Science for Serious Disease













John Beadle CEO

March 2017



PsiOxus R&D Pipeline



clinical and pre-clinical stage products

Pipeline								
Program	Virus	Indication / Description	Research	Preclinical	Phase 1	Next Data Read-Out	Development Partner	Commercial Rights
Enadenotucirev combinations 	Unarmed Enadenotucirev	Ovarian Cancer + Paclitaxel	Clinical Stage			Data Available in 2017	 Bristol-Myers Squibb	 PsiOxus THERAPEUTICS
		Carcinomas + nivolumab	Clinical Stage			Data Available in 2018		 PsiOxus THERAPEUTICS
T-SiGn viruses 	NG-348	MiTe based T-SiGn Virus	IND enabling			Phase I Initiation in 2017	 Bristol-Myers Squibb	 Bristol-Myers Squibb
	NG-350a	Antibody based T-SiGn Virus	Pre-clinical			Phase I Initiation in 2018		 PsiOxus THERAPEUTICS
	NG-347	MiTe + cytokine based T-SiGn Virus	Pre-clinical			Phase I Initiation In 2018		 PsiOxus THERAPEUTICS
	NG-345	Cytokine based T-SiGn Virus	Pre-clinical			Phase I Initiation In 2018		 PsiOxus THERAPEUTICS
	NG-600 series	Anti-stromal T-SiGn viruses	Lead discovery			Phase I Initiation TBC		 PsiOxus THERAPEUTICS
	Follow on T-SiGn programs	Multiple T-SiGn viruses in research phase	Research			Phase I Initiation TBC		 PsiOxus THERAPEUTICS



The Mechanism of Action study


- Patients with resectable, primary colon cancer
- EnAd delivered by IT or IV administration prior to surgery
- Administration:
 - Intra-tumoral injection (d1)
 - Intravenous infusion (d1,3,5)





Clinical PoC:

IV delivery is effective at virus delivery throughout the tumor




- **66% of slides** had 20% or more nuclear staining following IV delivery (vs 34% with IT)
- **No slides** had zero nuclear staining following IV delivery (vs 12% with IT)

10 patients with primary CRC. Half received IV and half received IT (via colonoscopy) enadenotucirev. After surgical resection the tumors were cut into multiple blocks and multiple sections from each block were stained for viral hexon and a blinded independent pathologist assessed each for the % of tumor cells +ve for nuclear staining.



Tumor-Specific Immuno Gene Therapy: T-SIGn

Armed Enadenotucirev to Deliver Immuno-Therapeutics to Local Tumor Sites of Action



Local immunotherapy delivery to tumors

- Effective concentrations in local microenvironments
- Minimized systemic exposure for improved safety




NG-348:

T-cell Activation Mechanism



Bristol-Myers Squibb

Antigen-dependent T cell receptor (TCR)-mediated T-cell activation by an APC



Antigen-independent TCR-mediated T-cell activation by NG-348 infected tumor cells

